- Trials with a EudraCT protocol (120)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
120 result(s) found for: Capsule endoscopy.
Displaying page 2 of 6.
EudraCT Number: 2021-006656-14 | Sponsor Protocol Number: MH002-PC-201 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:MRM Health NV | |||||||||||||
Full Title: Exploratory Study to Evaluate Safety, Mechanistic and Clinical Effects of MH002 in Subjects with Acute Pouchitis | |||||||||||||
Medical condition: Acute Pouchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015136-14 | Sponsor Protocol Number: FP-0110-201 | Start Date*: 2009-11-20 | |||||||||||
Sponsor Name:FORMAC Pharmaceuticals NV | |||||||||||||
Full Title: Modified release metronidazole for the treatment of pouchitis after colectomy with ileo-anal pouch anastomosis for ulcerative colitis: a pharmacokinetic study | |||||||||||||
Medical condition: Pouchitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001156-19 | Sponsor Protocol Number: D9614C00007 | Start Date*: 2012-03-08 | |||||||||||
Sponsor Name:AstraZeneca LP | |||||||||||||
Full Title: A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive with Endoscopically-Proven Gastroeso... | |||||||||||||
Medical condition: Pediatric patients 1 to 11 years old, inclusive, with endoscopically-proven GERD. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002025-19 | Sponsor Protocol Number: RPC01-2201 | Start Date*: 2015-12-30 | |||||||||||||||||||||
Sponsor Name:Celgene International II Sarl (CISII) awholly owned subsidiary of Celgene Corporation | |||||||||||||||||||||||
Full Title: A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Act... | |||||||||||||||||||||||
Medical condition: Moderately to Severely Active Crohn's Disease | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) PL (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-005169-39 | Sponsor Protocol Number: D9914C00002 | Start Date*: 2005-08-11 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d. | ||
Medical condition: Symptoms from the upper gastrointestinal tract | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (Completed) DE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004506-15 | Sponsor Protocol Number: TAK-390MR_204 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Takeda Development Centre Europe Ltd. | |||||||||||||
Full Title: A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to ... | |||||||||||||
Medical condition: Symptomatic nonerosive GERD in paediatric subjects aged 1 to 11 years | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Prematurely Ended) PT (Completed) PL (Trial now transitioned) LT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000693-31 | Sponsor Protocol Number: COLO CP-01 | Start Date*: 2005-06-17 |
Sponsor Name:Colotech A/S | ||
Full Title: An international, multi centre, randomised, parallel group, prospective, double blind, placebo controlled clinical trial evaluating the efficacy and safety of a combination treatment administered o... | ||
Medical condition: Patients who have had removal of polyp in colon or rectum within 3 months. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005019-30 | Sponsor Protocol Number: IM047-023 | Start Date*: 2022-12-09 | |||||||||||
Sponsor Name:Celgene International II Sarl | |||||||||||||
Full Title: A Phase 2/3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Participants with Moderately... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004676-37 | Sponsor Protocol Number: GD3-170-302 | Start Date*: 2005-04-27 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A randomized, double-blind study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with C.difficile-associated diarrhea | |||||||||||||
Medical condition: C. difficile-associated diarrhea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) DE (Completed) CZ (Completed) DK (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005422-31 | Sponsor Protocol Number: COX189A2425 | Start Date*: 2006-05-05 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A 16-day, randomized, double-blind, double-dummy, placebo-controlled, parallel-group trial comparing lumiracoxib 100mg o.d. with naproxen 500 mg b.i.d. plus omeprazole 20mg o.d. and placebo in heal... | ||
Medical condition: Healthy volunteers. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002472-15 | Sponsor Protocol Number: FE999907 CS004 | Start Date*: 2005-09-22 | |||||||||||
Sponsor Name:Ferring Laegemidler A/S | |||||||||||||
Full Title: The effect on mucosal healing with Pentasa® Sachet 4 g in mild to moderate active small bowel Crohn's disease, evaluated with video capsule endoscopy after 6 and 12 weeks treatment. A pilot study. | |||||||||||||
Medical condition: Mild to moderate active Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001681-15 | Sponsor Protocol Number: TAK-390MR_207 | Start Date*: 2012-10-17 | |||||||||||||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd | |||||||||||||||||||||||
Full Title: A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenan... | |||||||||||||||||||||||
Medical condition: Heartburn and Erosive Esophagitis in Adolescent Subjects | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000419-90 | Sponsor Protocol Number: T-EE05-135 | Start Date*: 2006-06-16 |
Sponsor Name:TAP Pharmaceutical Products Inc. | ||
Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis | ||
Medical condition: Erosive esophagitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) HU (Completed) SK (Completed) CZ (Completed) LT (Completed) LV (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000189-19 | Sponsor Protocol Number: DSC/06/2357/23 | Start Date*: 2007-08-06 | |||||||||||
Sponsor Name:Italfarmaco S.p.A. | |||||||||||||
Full Title: Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease | |||||||||||||
Medical condition: Moderate-to-severe active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000082-16 | Sponsor Protocol Number: ACESO | Start Date*: 2021-01-21 | |||||||||||
Sponsor Name:EsoCap AG | |||||||||||||
Full Title: A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis | |||||||||||||
Medical condition: Active eosinophilic esophagitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006258-99 | Sponsor Protocol Number: ECAMTEHP0012012 | Start Date*: 2012-04-02 | |||||||||||
Sponsor Name:Sección de Digestivo. Hospital Comarcal de Laredo | |||||||||||||
Full Title: FIRST-LINE ERADICATOR THERAPY OF HELICOBACTER PYLORI INFECTION: OPEN CLINICAL TRIAL, RANDOMIZED, MULTICENTRE, THREE-ARMED, COMPARING THE CLASSICAL TRIPLE THERAPY VERSUS A MODIFIED SEQUENTIAL THERAP... | |||||||||||||
Medical condition: Clinical situations where it is recommended the eradication of Helicobacter pylori: - Gastric or duodenal ulcer (active or not) and duodenal erosions - Gastric MALT lymphoma - First-degree relat... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004090-50 | Sponsor Protocol Number: CT-OST-122-02 | Start Date*: 2020-02-07 |
Sponsor Name:ONCOSTELLAE S.L. | ||
Full Title: A Phase Ib/IIa, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with modera... | ||
Medical condition: Moderate to severe ulcerative colitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004179-11 | Sponsor Protocol Number: 2018-4898 | Start Date*: 2019-06-03 |
Sponsor Name:Radboudumc | ||
Full Title: Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, pa... | ||
Medical condition: Hereditary hemorrhagic telangiectasia (HHT) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) DE (Ongoing) FR (Completed) IT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003558-26 | Sponsor Protocol Number: ABX464-103 | Start Date*: 2019-12-10 | |||||||||||
Sponsor Name:ABIVAX | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with... | |||||||||||||
Medical condition: Moderate to Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SI (Completed) CZ (Completed) DE (Completed) SK (Completed) HU (Completed) PL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001189-15 | Sponsor Protocol Number: T-EE04-086 | Start Date*: 2006-03-07 |
Sponsor Name:TAP Pharmaceutical Products Inc. | ||
Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis | ||
Medical condition: Erosive esophagitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) LT (Completed) CZ (Completed) GB (Prematurely Ended) LV (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
